Pharmacokinetics, dose strategies, calorie planning, and the physiology behind why the tracker is built the way it is. Written for people on tirzepatide, semaglutide, and compounded peptides who want to understand what's actually happening, not just follow a regimen.
A 5-day half-life sounds simple until you're on your fourth weekly injection and your active blood level is ~2.5× your dose. The math behind why Mounjaro and Zepbound keep ramping for about a month.
Read →Why daily calorie targets fail on Ozempic, Wegovy, Mounjaro, and Zepbound — and how a 7-day rolling window fixes the problem without asking you to overeat.
Read →Nausea patterns on tirzepatide and semaglutide are predictable. Knowing when the peak lands (and when it goes away) is the difference between white-knuckling it and planning around it.
Read →Same peptide, three deliveries. The practical differences between Ozempic, Wegovy, and compounded semaglutide — and why the tracker treats them identically.
Read →An educational overview of nausea, reflux, sulfur burps, constipation, diarrhea, and fatigue on Ozempic, Wegovy, Mounjaro, and Zepbound — what causes them, what users commonly try, and when to call a prescriber.
Read →A founder essay on why MyFitnessPal-style daily logging structurally fails ADHD users — and the principles that an ADHD-friendly nutrition tracker actually has to satisfy.
Read →